Responsibility in Drug Advertising Act of 2024
Latest Action
Referred to the House Committee on Energy and Commerce.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Responsibility in Drug Advertising Act of 2024 is a bill introduced in the 118th Congress aimed at regulating drug advertising practices. While the official summary and full text of the bill are not available, the bill was referred to the House Committee on Energy and Commerce, which typically oversees health-related legislation. The bill falls under the health policy area and appears to focus on ensuring accountability in how drugs are marketed to the public.
This bill seeks to address drug advertising practices but lacks publicly available details on its specific provisions and regulatory mechanisms.
- The bill is titled the Responsibility in Drug Advertising Act of 2024 and was introduced in the House of Representatives.
- It was referred to the House Committee on Energy and Commerce on July 25, 2024.
- The bill is categorized under the health policy area and is currently marked as failed or expired.
['Consumers who receive drug advertisements', 'Healthcare providers who rely on accurate drug information', 'Regulatory agencies such as the Food and Drug Administration (FDA)', 'Pharmaceutical companies subject to advertising regulations']
['Lack of publicly available full bill text limits understanding of enforcement mechanisms and regulatory scope', 'Unclear funding or resource allocation for implementation and oversight', 'Potential challenges in defining and monitoring responsible advertising standards', "Uncertainty about the bill's impact on existing drug advertising regulations"]
The bill was introduced during the 118th Congress and referred to the House Committee on Energy and Commerce, which handles health-related legislation including drug regulation. The bill is currently classified as failed or expired, indicating it did not advance through the legislative process. No additional legislative history or summary information is available.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential changes in pharmaceutical advertising practices if the bill had passed', 'Possible increased regulatory oversight on drug marketing', 'Impact on consumer awareness and healthcare decision-making through altered advertising standards']
The absence of an official summary and full bill text restricts comprehensive analysis and public understanding of the bill's scope and impact. Transparency in legislative documentation is essential for informed oversight and stakeholder engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.